- General Manager to be appointed
- Herman Schwietert - General Manager, PRC and Hong Kong
- Daryl Yap - Head of PharmaLink, Hong Kong
- Andrew Lane - Head of PharmaLink, Korea
- Peter Mayrick - Managing Director, Australia/New Zealand
Herman Schwietert - General Manager, PRC and Hong Kong
Herman Schwietert assumed the role of General Manager for PharmaLink China in June 2007.
Prior to PharmaLink, Herman took on various roles in the pharmaceutical industry, mainly in marketing and sales, and General Management.
From 2002 to 2006, he worked and lived in Shanghai as Marketing and Sales Manager for Organon China. After which, he moved to Hungary as General Manager. His international experience also includes the Netherlands and Ukraine.
Herman received a Master of Science Degree in Pharmacy from the State University of Groningen, the Netherlands.
Daryl Yap - Head of PharmaLink, Hong Kong
Daryl has been working in the pharmaceutical industry for 20 years.
Prior to joining Pharmalink Hong Kong in 2008, Daryl held various positions in the areas of sales and marketing with Glaxo (Hong Kong), Schering- Plough (Hong Kong), Merck Sharp and Dohme (China), Amgen (Greater China). His last position was Head Business Unit - Oncology with Novartis Pharmaceuticals (Hong Kong) Ltd.
Daryl holds an MBA from University of Hull (UK).
Andrew Lane - Head of PharmaLink, Korea
Andrew Lane holds degree in Accountancy and Business Management from Auckland University of Technology.
He spent the last 14 years in the pahrmacuetical industry - 7 years at Novartis pharmaceuticals and another 7 at DKSH in distribution.
Andrew's keen insight into both manufacturing and services makes him the business partner of choice for pharmaceutical clients in Korea.
Peter Mayrick - Managing Director, Australia/New Zealand
Peter Mayrick has more than 18 years of experience in commercialising pharmaceuticals in Australia, New Zealand and South East Asia. Before joining PharmaLink in Australia (previously Innovex), Peter took on sales, sales management and marketing roles at Astra Pharmaceuticals and AstraZeneca for a period of 10 years.
An active advocate of Medicine Australia's initiatives, Peter has been chairing the Value of Medicines Strategic Committee for the past 3 years. He is currently a member of the Industry Image Strategic Committee. Peter's knowledge in commercialising prescription and OTC medicines in Australia and New Zealand provides valuable partnership opportunities for clients in these countries.
A subsidiary of INVIDA.